Cellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Tuesday morning. The firm issued a sell rating on the biotechnology company’s stock.

A number of other analysts also recently issued reports on CLLS. JMP Securities restated a market outperform rating and set a $6.00 price target on shares of Cellectis in a report on Friday, May 31st. Oppenheimer dropped their target price on shares of Cellectis from $11.00 to $10.00 and set an outperform rating for the company in a report on Wednesday, June 12th.

Cellectis Stock Down 6.3 %

Shares of NASDAQ CLLS opened at $2.25 on Tuesday. The company has a 50 day simple moving average of $2.18 and a 200-day simple moving average of $2.43. The company has a market capitalization of $125.06 million, a P/E ratio of -1.74 and a beta of 3.09. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. Cellectis has a 1 year low of $0.96 and a 1 year high of $3.77.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. The business had revenue of $9.50 million during the quarter, compared to the consensus estimate of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. On average, equities research analysts predict that Cellectis will post -0.54 earnings per share for the current year.

Institutional Trading of Cellectis

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in Cellectis in the 2nd quarter valued at approximately $29,000. Principal Financial Group Inc. boosted its position in Cellectis by 6.2% in the 1st quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company’s stock valued at $1,125,000 after buying an additional 24,906 shares during the period. Baillie Gifford & Co. boosted its position in Cellectis by 1.3% in the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after buying an additional 10,605 shares during the period. Finally, Long Focus Capital Management LLC boosted its position in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.